Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDD-2101 in Healthy Volunteers
NCT06570668Phase 1Completed
- Sponsor
- Centre for Chinese Herbal Medicine Drug Development
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mazirenwan in functional constipation (FC) (5 arms), sponsored by Centre for Chinese Herbal Medicine Drug Development. Primary endpoint: Safety and Tolerability of CDD-2101 at 26 days. Started May 2024; status: completed.
02
Drugs
mazirenwan
03
Conditions
functional constipation (FC)
Beyond the preview
Go deeper on NCT06570668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06570668.